FNA News and Press, Paragon 28 Inc. From 03/08/22

Paragon 28, Inc. (FNA) Q4 2021 Earnings Conference Call March 08, 2022, 04:30 PM ET Company Participants Matt Bacso - Gilmartin Group Albert DaCosta - Chairman and CEO Stephen Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of ...

Paragon 28 press release (NYSE:FNA): Q4 Net loss $6.2M Revenue of $42.8M (+22.1% Y/Y) beats by $1.36M. For further details see: Paragon 28 reports Q4 results

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021. 2021 Highligh...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 8, 2022. The co...

Disior advances Paragon 28’s SMART 28™ strategy, providing a comprehensive 3D analytics and pre-operative planning platform, and will immediately accelerate internal research programs Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28ȁ...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended Decembe...

Paragon 28 (NYSE:FNA) perks up 1.4% premarket after announcing that the FDA has given 501(k) marketing clearance to its R3ACT Stabilization System. The R3ACT Stabilization System is expected to commercially launch in early 2022. The addition of the R3ACT Stabilization Syst...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT™ Stabilization ...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24 th Annual Needham Gro...

Paragon 28, Inc. (NYSE: FNA ) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufa...